SB8

BIOLOGICAL2 trials

Sponsors

Samsung Bioepis Co., Ltd.

Conditions

HealthyLung CancerNon-small Cell Lung Cancer

Phase 1

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

CompletedNCT02453672

Samsung Bioepis Co., Ltd.Healthy

Start: 2015-04-30End: 2015-09-30Updated: 2019-06-03

Phase 3

A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

CompletedNCT02754882

Samsung Bioepis Co., Ltd.Lung Cancer, Non-small Cell Lung Cancer

Start: 2016-07-05End: 2018-10-09Updated: 2024-12-16

Related Papers

Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.

2024-01-161 citations

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.

2020-09-1913 citations